{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:26:15Z","timestamp":1787239575690,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100023544","name":"National Taiwan University Hospital Hsin-Chu Branch","doi-asserted-by":"publisher","award":["113-HCH104"],"award-info":[{"award-number":["113-HCH104"]}],"id":[{"id":"10.13039\/501100023544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-112-2314-B-002-30"],"award-info":[{"award-number":["MOST-112-2314-B-002-30"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40256-025-00760-x","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T16:25:21Z","timestamp":1756139121000},"page":"83-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease"],"prefix":"10.1007","volume":"26","author":[{"given":"Donna Shu-Han","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yun","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9690-6573","authenticated-orcid":false,"given":"Chih-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"760_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709\u201333.","journal-title":"Lancet"},{"key":"760_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398:786\u2013802.","journal-title":"Lancet"},{"key":"760_CR3","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527\u201339.","journal-title":"J Am Coll Cardiol"},{"key":"760_CR4","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.jacc.2019.02.071","volume":"73","author":"N Bansal","year":"2019","unstructured":"Bansal N, Zelnick L, Bhat Z, Dobre M, He J, Lash J, et al. Burden and outcomes of heart failure hospitalizations in adults with chronic kidney disease. J Am Coll Cardiol. 2019;73:2691\u2013700.","journal-title":"J Am Coll Cardiol"},{"key":"760_CR5","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.jacc.2019.09.059","volume":"74","author":"D Kotecha","year":"2019","unstructured":"Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, et al. Impact of renal impairment on beta-blocker efficacy in patients with heart failure. J Am Coll Cardiol. 2019;74:2893\u2013904.","journal-title":"J Am Coll Cardiol"},{"key":"760_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/sdi.12878","volume":"33","author":"B Roehm","year":"2020","unstructured":"Roehm B, Gulati G, Weiner DE. Heart failure management in dialysis patients: many treatment options with no clear evidence. Semin Dial. 2020;33:198\u2013208.","journal-title":"Semin Dial"},{"key":"760_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"760_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"760_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018298","volume":"10","author":"X Li","year":"2021","unstructured":"Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da Silva AA, et al. Direct cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure. J Am Heart Assoc. 2021;10: e018298.","journal-title":"J Am Heart Assoc"},{"key":"760_CR10","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kov\u00e1cs \u00c1, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20:1690\u2013700.","journal-title":"Eur J Heart Fail"},{"key":"760_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.12182","volume":"16","author":"S Macha","year":"2014","unstructured":"Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16:215\u201322.","journal-title":"Diabetes Obes Metab"},{"key":"760_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00592-022-02015-6","volume":"60","author":"Z He","year":"2023","unstructured":"He Z, Lam K, Zhao W, Yang S, Li Y, Mo J, et al. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis\/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment. Acta Diabetol. 2023;60:401\u201311.","journal-title":"Acta Diabetol"},{"key":"760_CR13","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297\u2013317.","journal-title":"Eur Heart J"},{"key":"760_CR14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","volume":"106","author":"DS-H Lin","year":"2021","unstructured":"Lin DS-H, Lee J-K, Chen W-J. Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab. 2021;106:2133\u201345.","journal-title":"J Clin Endocrinol Metab"},{"key":"760_CR15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"760_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129\u201339.","journal-title":"N Engl J Med"},{"key":"760_CR17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"760_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"760_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","volume":"10","author":"RJ Perry","year":"2019","unstructured":"Perry RJ, Rabin-Court A, Song JD, Cardone RL, Wang Y, Kibbey RG, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019;10:548.","journal-title":"Nat Commun"},{"key":"760_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10242","volume":"3","author":"G Cianciolo","year":"2019","unstructured":"Cianciolo G, De Pascalis A, Capelli I, Gasperoni L, Di Lullo L, Bellasi A, et al. Mineral and electrolyte disorders with SGLT2i therapy. JBMR Plus. 2019;3: e10242.","journal-title":"JBMR Plus"},{"key":"760_CR21","volume":"2015","author":"A Kaur","year":"2015","unstructured":"Kaur A, Winters SJ. Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin. Endocrinol Diabetes Metab Case Rep. 2015;2015: 150042.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"760_CR22","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1002\/ehf2.13622","volume":"8","author":"J Kolwelter","year":"2021","unstructured":"Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, et al. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;8:5327\u201337.","journal-title":"ESC Heart Fail"},{"key":"760_CR23","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1038\/s41598-022-07395-x","volume":"12","author":"L Cheng","year":"2022","unstructured":"Cheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, et al. Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms. Sci Rep. 2022;12:3525.","journal-title":"Sci Rep"},{"key":"760_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108588","volume":"37","author":"BK Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer BK, Hauske SJ, Chilton R, Mann JFE, Gullestad L, Fitchett D, et al. Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes. J Diabetes Complicat. 2023;37: 108588.","journal-title":"J Diabetes Complicat"},{"key":"760_CR25","doi-asserted-by":"publisher","first-page":"1243530","DOI":"10.3389\/fcdhc.2023.1243530","volume":"4","author":"J Barreto","year":"2023","unstructured":"Barreto J, Campos-Staffico AM, Nadruz W, Quinaglia T, Sposito AC. The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives. Front Clin Diabetes Healthc. 2023;4:1243530.","journal-title":"Front Clin Diabetes Healthc"},{"key":"760_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.016173","volume":"9","author":"A Zanchi","year":"2020","unstructured":"Zanchi A, Burnier M, Muller M-E, Ghajarzadeh-Wurzner A, Maillard M, Loncle N, et al. Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial. J Am Heart Assoc. 2020;9: e016173.","journal-title":"J Am Heart Assoc"},{"key":"760_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.854230","volume":"9","author":"A Zanchi","year":"2022","unstructured":"Zanchi A, Pruijm M, Muller M-E, Ghajarzadeh-Wurzner A, Maillard M, Dufour N, et al. Twenty-four hour blood pressure response to empagliflozin and its determinants in normotensive non-diabetic subjects. Front Cardiovasc Med. 2022;9: 854230.","journal-title":"Front Cardiovasc Med"},{"key":"760_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112355","volume":"9","author":"C-S Hung","year":"2014","unstructured":"Hung C-S, Lee J-K, Yang C-Y, Hsieh H-R, Ma W-Y, Lin M-S, et al. Measurement of visceral fat: should we include retroperitoneal fat? PLoS ONE. 2014;9: e112355.","journal-title":"PLoS ONE"},{"key":"760_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/jch.13771","volume":"22","author":"K Kario","year":"2020","unstructured":"Kario K, Matsuda S, Nagahama S, Kurose Y, Sugii H, Teshima T, et al. Single-pill combination of cilnidipine, an L-\/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: the HOPE-combi survey. J Clin Hypertens (Greenwich). 2020;22:457\u201364.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"760_CR30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/01.CIR.100.4.354","volume":"100","author":"SS Franklin","year":"1999","unstructured":"Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation. 1999;100:354\u201360.","journal-title":"Circulation"},{"key":"760_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000004007","author":"SF Nielsen","year":"2025","unstructured":"Nielsen SF, Duus CL, Buus NH, Bech JN, Mose FH. The effects of empagliflozin on systemic haemodynamic function: three randomized, placebo-controlled trials. J Hypertens. 2025. https:\/\/doi.org\/10.1097\/HJH.0000000000004007.","journal-title":"J Hypertens"},{"key":"760_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ekir.2024.10.019","volume":"10","author":"SF Nielsen","year":"2025","unstructured":"Nielsen SF, Duus CL, Buus NH, Bech JN, Mose FH. Randomized, placebo-controlled trial on the renal and systemic hemodynamic effects of empagliflozin. Kidney Int Rep. 2025;10:134\u201344.","journal-title":"Kidney Int Rep"},{"key":"760_CR33","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1681\/ASN.2013060601","volume":"25","author":"R Agarwal","year":"2014","unstructured":"Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR. Assessment and management of hypertension in patients on dialysis. J Am Soc Nephrol. 2014;25:1630\u201346.","journal-title":"J Am Soc Nephrol"},{"key":"760_CR34","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1053\/j.ajkd.2006.07.005","volume":"48","author":"Z Li","year":"2006","unstructured":"Li Z, Lacson E, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis. 2006;48:606\u201315.","journal-title":"Am J Kidney Dis"},{"key":"760_CR35","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1525-139X.2007.00339.x","volume":"20","author":"E Lacson","year":"2007","unstructured":"Lacson E, Lazarus JM. The association between blood pressure and mortality in ESRD-not different from the general population? Semin Dial. 2007;20:510\u20137.","journal-title":"Semin Dial"},{"key":"760_CR36","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","volume":"143","author":"K Philippaert","year":"2021","unstructured":"Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, Soni S, Byrne NJ, et al. Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143:2188\u2013204.","journal-title":"Circulation"},{"key":"760_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3389\/fphar.2020.00413","volume":"11","author":"B Horv\u00e1th","year":"2020","unstructured":"Horv\u00e1th B, H\u00e9zs\u0151 T, Kiss D, Kistam\u00e1s K, Magyar J, N\u00e1n\u00e1si PP, et al. Late sodium current inhibitors as potential antiarrhythmic agents. Front Pharmacol. 2020;11:413.","journal-title":"Front Pharmacol"},{"key":"760_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00424-017-2079-7","volume":"470","author":"S Yu","year":"2018","unstructured":"Yu S, Li G, Huang CL-H, Lei M, Wu L. Late sodium current associated cardiac electrophysiological and mechanical dysfunction. Pflugers Arch. 2018;470:461\u20139.","journal-title":"Pflugers Arch"},{"key":"760_CR39","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RCI, Fiolet JWT, Stienen GJM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia. 2017;60:568\u201373.","journal-title":"Diabetologia"},{"key":"760_CR40","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018;61:722\u20136.","journal-title":"Diabetologia"},{"key":"760_CR41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/clinpract12040059","volume":"12","author":"D Antwi-Amoabeng","year":"2022","unstructured":"Antwi-Amoabeng D, Sathappan S, Beutler BD, Ulanja MB, Awad M, Gullapalli N, et al. Association between empagliflozin use and electrocardiographic changes. Clin Pract. 2022;12:557\u201364.","journal-title":"Clin Pract"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00760-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00760-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00760-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:35:38Z","timestamp":1767796538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00760-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00760-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Donna Shu-Han Lin, Hao-Yun Lo, Chung-Wei Yang, and Chih-Cheng Wu have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing may be available to investigators whose proposed use of the data has been approved by an independent review committee, after reasonable request directly to the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"Conceptualization: DSH Lin, CC Wu. Data curation: HY Lo. Formal analysis: CW Yang. Funding acquisition: CC Wu. Investigation: DSH Lin, HY Lo. Methodology: DSH Lin. Project administration, resources, software: CW Yang. Supervision: CC Wu. Validation: HY Lo. Visualization: CW Yang. Writing \u2013 original draft: DSH Lin. Writing \u2013 review & editing: DSH Lin, CC Wu.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This is a single-arm, open-label, dose-escalating safety study required by the IRB of the NTUH before the commencement of two randomized controlled studies (IRB numbers 202301126MINC and 202301140MINC) registered at ClinicalTrials.gov (EMPA-PRED and EMPA-RRED studies, numbers NCT06249945 and NCT06249932).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study patients provided written informed consent to participate in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}